KBKamal A. Badr

Kamal A. Badr

*This is an algorithmically generated author record based on publicly available information.

Kamal A. Badr has a total of 3 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bioequivalence evaluation of two cariprazine hard capsule formulations

    by Mamdouh R. Rezk, Kamal A. Badr, Ahmed Abd El Hamid Hosny, Aya M. Abdel Magid

    Cariprazine, a third-generation antipsychotic, is indicated for schizophrenia and bipolar I disorder. Affordable formulations are essential for improving access and adherence, particularly in resource-limited settings. We aimed to assess the bioequivalence, safety, and tolerability of a newly developed generic hard capsule Vocarzine (1.5 mg) compared to a branded reference product of cariprazine hard capsule (Reagila®) under fasting conditions in healthy adult participants. In a randomized, open-label, single-dose, two-period, two-sequence crossover design, 30 healthy male and female participants received a single oral dose of either the test or reference product, with 4-week washout period. Pharmacokinetics were evaluated using validated LC–MS/MS methods. Bioequivalence was concluded if the 90% confidence intervals (CIs) for the geometric mean ratios (GMRs) of peak plasma concentration (C max ) and area under the concentration–time curve from time zero to 72 h (AUC 0-72h ) fell within 80–125%. Twenty-nine participants completed the study. The GMR (90% CI) for C max was 91.92% (85.07–99.33%) and for AUC 0-72h was 92.85% (88.86–97.02%), both within the bioequivalence acceptance range (80–125%). Both formulations were well tolerated; mild nausea was the most common adverse event, and no serious adverse events were reported. The two hard capsule formulations were bioequivalent, in terms of rate and extent of absorption, with a comparable safety profile, supporting the use of vocarzine as a safe, effective, and potentially cost-saving alternative. Clinical trial number: The ClinicalTrials.gov registration number is NCT07121868, retrospectively registered on August 13, 2025.


  • Open Access

    Bioequivalence assessment of imeglimin hydrochloride tablet, a novel glimin-class antidiabetic agent

    by Mamdouh R. Rezk, Kamal A. Badr, Ahmed Abd El Hamid Hosny, Aya M. AbdelMagid

    Purpose: While imeglimin’s, oral antidiabetic agent, efficacy and safety are established in Japanese and Western populations, pharmacokinetic data from Middle Eastern and African cohorts remain limited. This study aimed to evaluate the bioequivalence of test and reference imeglimin formulations under fasting conditions in healthy Egyptian adults. Methods: In a randomized, open-label, two-period, two-sequence crossover trial, healthy male and female adults received a single 500 mg oral dose of either formulation under fasting conditions, separated by a one-week washout. Adverse events (AEs) were assessed via direct questioning, participants’ reporting, vital signs monitoring, and clinical laboratory evaluations. Plasma concentrations were measured up to 72 h post-dose, and pharmacokinetic parameters were derived using non-compartmental analysis. Bioequivalence was concluded if the geometric mean ratios (GMRs) and 90% confidence intervals (CIs) for peak plasma concentration (C max ), area under the concentration–time curve to 72 h (AUC 0-72 ), and to infinity (AUC 0–inf ) were within 80–125%. Results: In 29 healthy participants, all pharmacokinetic endpoints met bioequivalence criteria. GMR (90% CI) for each pharmacokinetic endpoint were: C max 101.75% (94.42–109.64); AUC 0–72 100.66% (94.28–107.46); AUC 0–inf 100.13% (93.77–106.92). The intrasubject variability was low (14–17%). Both formulations were well tolerated, with only mild transient adverse events (headache, abdominal pain) and no serious events. Conclusion: The test formulation of imeglimin was bioequivalent to the reference, with a favorable safety profile. This first pharmacokinetic and bioequivalence study in a Middle Eastern/African population supports regulatory approval and enhances opportunities for affordable access to imeglimin in type 2 diabetes management. Clinical trial number. The ClinicalTrials.gov registration number is NCT07127094, retrospectively registered on August 15, 2025. Graphical


  • Open Access

    Bioequivalence of Two Perampanel Oral Suspension Formulations in Healthy Subjects: A Randomized Crossover Study

    by Aya M. AbdelMagid, Kamal A. Badr, Mamdouh R. Rezk

    Background and Objective Perampanel has been approved for the adjunctive treatment of partial-onset seizures and primary generalized tonic-clonic seizures. The oral suspension formulation benefits patients who have difficulty swallowing tablets. The unavailability of an affordable generic perampanel oral suspension formulation increased the need for a cheaper bioequivalent alternative to the marketed reference product. The study aimed to assess the bioequivalence of two formulations of perampanel oral suspension (0.5 mg/mL) administered under fasting conditions focusing on providing a cost-effective and accessible alternative to current formulations. Methods This was an open-label, two-period, two-sequence, crossover, bioequivalence study conducted under fasting conditions. Healthy subjects were randomized to receive single doses of perampanel oral suspension (12 mg), Lepsiramp and Fycompa® separated by a 6-week washout period. The maximum concentration and area under the concentration–time curve up to 72 h were the primary pharmacokinetic parameters used to assess bioequivalence. Results The geometric mean ratio of test to reference formulations and 90% confidence interval were 109.55 (99.49–120.64) for maximum concentration and 98.15 (90.68–106.23) for the area under the concentration–time curve up to 72 h, which were within the 80–125% bioequivalence range. The adverse events were mild headache and dizziness. Conclusions The two oral suspension formulations were bioequivalent, safe, and well tolerated. This provides a beneficial affordable alternative for patients requiring non-tablet oral formulations. Clinical Trial Registration The ClinicalTrials.gov registration number is NCT06969963, retrospectively registered on 13 May, 2025.